RJA
RLAY icon

Raymond James & Associates’s Relay Therapeutics RLAY Stock Holding History

Raymond James & Associates’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$473K Buy
66,842
+29,865
+81% +$223K ﹤0.01% 3149
2024
Q2 		$241K Buy
36,977
+10,700
+41% +$73.1K ﹤0.01% 3501
2024
Q1 		$218K Buy
26,277
+7,871
+43% +$76.8K ﹤0.01% 3572
2023
Q4 		$203K Sell
18,406
-2,399
-12% -$20.2K ﹤0.01% 3519
2023
Q3 		$175K Sell
20,805
-14,803
-42% -$159K ﹤0.01% 3495
2023
Q2 		$447K Buy
+35,608
New +$443K ﹤0.01% 3008

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Raymond James & Associates's RLAY Position: Q3 2024 in Review

Raymond James & Associates increased its Relay Therapeutics (RLAY) stake by 81% in Q3 2024, buying an estimated $223K and bringing the position to 66,842 shares worth $473K. The position accounts for ﹤0.01% of the portfolio, ranked #3149.

Raymond James & Associates first reported a position in RLAY in Q2 2023 and has held it in 6 quarters since. 195 funds tracked by Wall St. Rank hold RLAY as of Q3 2024.

  • Raymond James & Associates held 66,842 shares of Relay Therapeutics worth $473K as of Q3 2024.
  • Raymond James & Associates bought 29,865 Relay Therapeutics shares in Q3 2024, an estimated $223K.
  • Relay Therapeutics made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #3149 holding.
  • Raymond James & Associates first reported a position in Relay Therapeutics in Q2 2023 and has held it in 6 quarters since.
  • 195 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.